Forte Biosciences, Inc. - FBRX STOCK NEWS

Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Chardan Annual Microbiome Medicines Summit on March 8, 2021. A webcast of the presentation will be available at this link at 1:00 PM Eastern Time, with a replay accessible until March 15, 2021. Forte is developing a live biotherapeutic, FB-401, for treating inflammatory skin diseases like atopic dermatitis in patients aged 2 and older, addressing significant unmet needs in this area.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Cowen Annual Health Care Conference on March 1, 2021. A webcast is scheduled for the same day at 4 PM ET, accessible via the company's website. Forte is developing FB-401, a live biotherapeutic for inflammatory skin diseases, targeting atopic dermatitis with significant unmet needs, particularly in pediatric patients. FB-401 has completed Phase 1/2a trials, and a new multi-center trial for various age groups is underway, expected to enhance treatment options.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced the issuance of equity inducement awards, granting 35,000 shares of common stock to new non-executive employees as a hiring incentive. The awards will vest over four years, with 25% vesting after one year and the remaining shares vesting monthly. These awards are issued under the 2020 Inducement Equity Incentive Plan and follow NASDAQ Listing Rule 5635(c)(4). Forte is developing FB-401 for treating inflammatory skin diseases, having completed Phase 1/2a trials and currently pursuing Phase 2 trials, particularly for pediatric patients with atopic dermatitis.

Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced that CEO Paul Wagner, Ph.D., will present at the Evercore ISI Annual HealthCONx Conference on December 3, 2020, at 11:20 AM ET. The presentation will be accessible via a webcast, which can be found on the company's investor relations page. Forte is focused on developing its live biotherapeutic, FB-401, for inflammatory skin diseases like atopic dermatitis, having recently initiated a clinical trial to assess its efficacy in patients aged 2 years and older.

Forte Biosciences, Inc. (NASDAQ: FBRX) announces the approval of an equity inducement award under NASDAQ rules, granting 25,000 shares of common stock to a new non-executive employee. The award vests over four years, with 25% vesting after the first year and the remainder in monthly increments. This inducement aims to attract talent in a competitive market. Forte is advancing its lead product, FB-401, for inflammatory skin diseases, having initiated a Phase 2 trial to address unmet needs in pediatric and adult patients with atopic dermatitis.

Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, from 2:40 to 3:10 PM ET. A webcast of the presentation will be accessible via Forte’s website and will remain available until November 25th. The company is focused on developing FB-401, a live biotherapeutic for inflammatory skin diseases, particularly atopic dermatitis. The drug has completed Phase 1/2a trials and a new multi-center trial is expected to enroll patients from age 2 and older.

Forte Biosciences, Inc. (NASDAQ: FBRX) reported significant advancements in its third quarter 2020 financial results. The company initiated a randomized clinical trial for FB-401 aimed at treating atopic dermatitis, with FDA granting Fast Track designation. Financially, Forte ended the quarter with approximately $20.2 million in cash, sufficient for the next 12 months, following a $46 million public offering post-quarter. Research and development expenses rose substantially, reflecting increased clinical development efforts. The net loss for the quarter was $5.1 million.

Forte Biosciences, Inc. (NASDAQ: FBRX) will announce its third quarter 2020 results after market close on November 9, 2020, followed by a conference call at 4:30 PM ET. The call will discuss the results and provide a business update. Forte is developing FB-401, a treatment for inflammatory skin diseases, currently in a multi-center clinical trial that includes pediatric, adolescent, and adult subjects aged 2 and older. The trial addresses a significant unmet need for effective therapies in pediatric atopic dermatitis.

Forte Biosciences, Inc. (NASDAQ: FBRX) has successfully closed its underwritten public offering, issuing 1,614,035 shares at a price of $28.50 per share, generating gross proceeds of approximately $46.0 million. The offering included 210,526 shares from the underwriters' option. The offering was managed by Ladenburg Thalmann, Truist Securities, and Chardan, with Brookline Capital Markets acting as co-manager. Forte, a clinical-stage biopharmaceutical company, is focused on developing its lead product, FB-401, for inflammatory skin diseases, particularly atopic dermatitis.